Related Experiment Video
Updated: May 20, 2026
08:36
Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
Published on: October 24, 2019
Evidence for steroidogenic potential in human prostate cell lines and tissues
Nigel C Bennett1, John D Hooper, Duncan Lambie
1School of Medicine, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia.
The American Journal of Pathology
|July 17, 2012
Summary
Prostate cancer cells can produce their own androgens, potentially leading to treatment resistance. This study found key enzymes for androgen synthesis in prostate tissues and cell lines, suggesting new therapeutic targets.
Area of Science:
- Endocrinology
- Oncology
- Biochemistry
Background:
- Malignant prostate cancer (PCa) is typically treated with androgen deprivation therapies (ADTs).
- Recurrent PCa often exhibits resistance to ADT, necessitating alternative treatment strategies.
- The potential for PCa to synthesize androgens de novo (self-sufficiency) remains an area of investigation.
Purpose of the Study:
- To investigate the presence and expression of key steroidogenic enzymes involved in de novo androgen synthesis in PCa.
- To determine if PCa cells can produce androgens independently of external sources.
- To explore the role of these enzymes in disease progression and potential therapeutic interventions.
Main Methods:
- Immunohistochemistry (IHC) was used to detect steroidogenic enzymes (CYP11A1, CYP17A1, HSD3β, HSD17β3) in human primary PCa, lymph node metastases (LNMs), and benign prostatic hyperplasia (BPH) tissues.
- Six prostate cell lines were analyzed for mRNA and protein expression of these enzymes.
- Endogenous synthesis of testosterone and 5α-dihydrotestosterone was assessed in vitro.
Main Results:
- All investigated steroidogenic enzymes were identified in PCa, LNMs, BPH, and prostate cell lines.
- CYP11A1, a rate-limiting enzyme, was expressed in both cancerous and non-cancerous prostate glands.
- While not all enzymes were always detectable at the protein level in vitro, all cell lines synthesized androgens from cholesterol.
Conclusions:
- Prostate cancer cells possess the enzymatic machinery for de novo androgen synthesis, contributing to potential androgen self-sufficiency.
- Expression patterns of steroidogenic enzymes change with disease progression, with CYP17A1 showing increased expression.
- Monitoring steroidogenic metabolites in PCa patients could offer valuable insights for guiding therapy interventions.
